Table 6.

Relation between MPO and Histones levels with the clinical characteristics of APLS patients’ group

		Histones (ng/ml)		P-value
		Median (IQR)	Range
Thrombotica	No	2.68 (2.16–3.2)	1.79–10.73	0.000**
	Yes	7.79 (4.61–9.76)	2.31–15.79
1ry/2ry APLSa	1ry	7.07 (3.2–9.66)	1.79–15.79	0.42
	2ry	4.61 (3.46–8.7)	2.15–12.95
Number of lab Positive Autoantibodieb	Single positivity	2.4 (2.16–4.07)	2.06–9.76	0.006**
	Double positivity	7.16 (3.46–9.39)	3.07–10.73
	Triple positivity	7.24 (4.12–9.66)	1.79–15.79
		MPO (ng/ml)		P-value
		Median (IQR)	Range
Thrombotica	No	3.73 (2.57–5.9)	1.43–8.76	0.001**
	Yes	7.62 (5.56–11.51)	1.79–16.92
1ry/2ry APLSa	1ry	6.21 (4.08–10.22)	2.04–16.92	0.446
	2ry	7.23 (5.39–11.73)	1.43–16.54
Number of lab Positive Autoantibodiesb	Single positivity	4.12 (3.13–7.3)	2.04–11.51	0.073**
	Double positivity	7.6 (5.56–8.02)	1.43–9.94
	Triple positivity	7.43 (5.39–11.73)	1.79–16.92

P-value > 0.05: Non-significant; P-value < 0.05*: Significant; P-value < 0.01**: Highly significant, ^a: Mann-Whitney test; ^b: Kruskall-Wallis’s test